{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T23:51:47Z","timestamp":1789689107893,"version":"4.0.1"},"reference-count":36,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ijantimicag.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,8,21]],"date-time":"2018-08-21T01:55:01Z","timestamp":1534816501000},"page":"474-484","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["In vitro activity of tigecycline and comparators (2014\u20132016) among key WHO \u2018priority pathogens\u2019 and longitudinal assessment (2004\u20132016) of antimicrobial resistance: a report from the T.E.S.T. study"],"prefix":"10.1016","volume":"52","author":[{"given":"Harald","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Blondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Dowzicky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0001","series-title":"Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics","year":"2017"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0002","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1080\/21505594.2016.1222343","article-title":"The global epidemiology of carbapenemase-producing Enterobacteriaceae","volume":"8","author":"van Duin","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0003","series-title":"Antimicrobial resistance surveillance in Europe 2015. Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net)","year":"2017"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0004","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ijantimicag.2016.04.021","article-title":"Tigecycline antimicrobial activity tested against clinical bacteria from Latin American medical centres: results from SENTRY antimicrobial surveillance program (2011\u20132014)","volume":"48","author":"Sader","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0005","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1128\/AAC.02684-13","article-title":"Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012)","volume":"58","author":"Sader","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0006","doi-asserted-by":"crossref","first-page":"5721","DOI":"10.1128\/AAC.01121-13","article-title":"Regional resistance surveillance program results for 12 Asia-Pacific nations (2011)","volume":"57","author":"Mendes","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0007","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12941-015-0085-1","article-title":"Global in vitro activity of tigecycline and comparator agents: Tigecycline Evaluation and Surveillance Trial 2004\u20132013","volume":"14","author":"Hoban","year":"2015","journal-title":"Ann Clin Microbiol Antimicrob"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000445022","article-title":"Antimicrobial susceptibility among European Gram-negative and Gram-positive isolates collected as part of the Tigecycline Evaluation and Surveillance Trial (2004\u20132014)","volume":"62","author":"Rodloff","year":"2017","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0009","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard","year":"2015"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0010","series-title":"Performance standards for antimicrobial susceptibility testing","year":"2017"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0011","series-title":"Tigecycline FDA prescribing information","year":"2016"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0012","series-title":"Breakpoint tables for interpretation of MICs and zone diameters. Version 7.1, 2017","year":"2017"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0013","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1517\/14656566.2014.914172","article-title":"Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches","volume":"15","author":"Karaiskos","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0014","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1093\/jac\/dku168","article-title":"Combination therapy for carbapenem-resistant Gram-negative bacteria","volume":"69","author":"Paul","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0015","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1093\/jac\/dkr239","article-title":"Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY antimicrobial surveillance program (2006\u201309)","volume":"66","author":"Gales","year":"2011","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0016","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/j.cmi.2015.05.022","article-title":"Contemporary resistance trends and mechanisms for the old antibiotics colistin, temocillin, fosfomycin, mecillinam and nitrofurantoin","volume":"21","author":"Giske","year":"2015","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0017","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1086\/429323","article-title":"Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections","volume":"40","author":"Falagas","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0018","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/jac\/dkx322","article-title":"High incidence of pandrug-resistant Acinetobacter baumannii isolates collected from patients with ventilator-associated pneumonia in Greece, Italy and Spain as part of the MagicBullet clinical trial","volume":"72","author":"Nowak","year":"2017","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0019","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1128\/AAC.00107-16","article-title":"Global dissemination of blaKPC into bacterial species beyond Klebsiella pneumoniae and in vitro susceptibility to ceftazidime\u2013avibactam and aztreonam\u2013avibactam","volume":"60","author":"Kazmierczak","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0020","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1111\/j.1469-0691.2011.03572.x","article-title":"Outbreak of KPC-3-producing, and colistin-resistant, Klebsiella pneumoniae infections in two Sicilian hospitals","volume":"17","author":"Mezzatesta","year":"2011","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0021","doi-asserted-by":"crossref","first-page":"3656","DOI":"10.1128\/AAC.05024-14","article-title":"Ceftazidime\u2013avibactam activity against multidrug-resistant Pseudomonas aeruginosa isolated in U.S. medical centers in 2012 and 2013","volume":"59","author":"Sader","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0022","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0023","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1586\/eri.09.108","article-title":"Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii: resistance mechanisms and implications for therapy","volume":"8","author":"Zavascki","year":"2010","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0024","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1128\/CMR.00040-09","article-title":"Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms","volume":"22","author":"Lister","year":"2009","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0025","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-resistant pathogens associated with healthcare-associated infections: summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132014","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0026","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.bjid.2017.03.006","article-title":"Resistance among Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Latin American countries: SMART 2013\u20132015","volume":"21","author":"Karlowsky","year":"2017","journal-title":"Braz J Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0027","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1099\/jmm.0.000421","article-title":"Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013\u20132015","volume":"66","author":"Karlowsky","year":"2017","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0028","doi-asserted-by":"crossref","first-page":"e00310","DOI":"10.1128\/mSphere.00310-16","article-title":"Global assessment of the activity of tigecycline against multidrug-resistant Gram-negative pathogens between 2004 and 2014 as part of the Tigecycline Evaluation and Surveillance Trial","volume":"2","author":"Giammanco","year":"2017","journal-title":"mSphere"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0029","series-title":"Antimicrobial resistance: global report on surveillance","year":"2014"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0030","first-page":"S173","article-title":"Analysis of resistance and vancomycin \u2018reverse creep\u2019 in Latin American Staphylococcus aureus: ten-year report of the SENTRY Antimicrobial Surveillance Program (1997\u20132006)","volume":"14","author":"Pic\u00e3o","year":"2008","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0031","first-page":"1970","article-title":"National burden of invasive methicillin-resistant Staphylococcus aureus infections, United States, 2011","volume":"173","author":"Dantes","year":"2013","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0032","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/jac\/dks354","article-title":"The emerging problem of linezolid-resistant Staphylococcus","volume":"68","author":"Gu","year":"2013","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0033","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.02803-15","article-title":"Linezolid surveillance results for the United States (LEADER Surveillance Program 2014)","volume":"60","author":"Flamm","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0034","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1179\/joc.2011.23.2.71","article-title":"Eight-year (2002\u20132009) summary of the linezolid (Zyvox\u00ae Annual Appraisal of Potency and Spectrum; ZAAPS) program in European countries","volume":"23","author":"Ross","year":"2011","journal-title":"J Chemother"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0035","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.diagmicrobio.2013.01.025","article-title":"An international activity and spectrum analysis of linezolid: ZAAPS Program results for 2011","volume":"76","author":"Flamm","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2018.07.003_bib0036","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1016\/j.bjid.2013.07.002","article-title":"Susceptibility rates in Latin American nations: report from a regional resistance surveillance program (2011)","volume":"17","author":"Jones","year":"2013","journal-title":"Braz J Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918301948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857918301948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:31:57Z","timestamp":1760376717000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857918301948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,10]]}},"alternative-id":["S0924857918301948"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.07.003","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro activity of tigecycline and comparators (2014\u20132016) among key WHO \u2018priority pathogens\u2019 and longitudinal assessment (2004\u20132016) of antimicrobial resistance: a report from the T.E.S.T. study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}